This study looks at how well different treatments work for people with Multiple Myeloma (MM), a type of blood cancer. There are two groups: people newly diagnosed with MM (NDMM) and people whose MM has come back or didn't respond to treatment (RRMM). The study uses real-world data, meaning it looks at how treatments work outside of a clinical trial setting. It is important to know that this is an observational study, so there will be no new treatments given, only observation of existing treatments.

To join, you must have started certain treatments for MM within the last 90 days or plan to start soon. The treatments include medicines like IMiDs (immune-modulating drugs), PIs (proteasome inhibitors), or newer types with special ways of working. You cannot join if you are in another MM trial or being treated for a different cancer.

• The study lasts for a certain time period but does not involve new treatments.
• You must have recent or planned treatment for MM to join.
• Participants must not be in another MM trial.